Comparing Attruby vs Tafamidis
| Attruby (acoramidis) | Tafamidis |
|
|---|
| Attruby (acoramidis) | Tafamidis |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis. Attruby may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Transthyretin-Related Amyloidosis, Hereditary Amyloidosis. Tafamidis may also be used for purposes not listed in this medication guide. View more |
Related suggestions Cardiomyopathy of Transthyretin-Mediated Amyloidosis
|
|||||||
| More about Attruby (acoramidis) | More about Tafamidis | ||||||||
| Ratings & Reviews | |||||||||
|
Be the first to share your experience with this drug. |
Tafamidis has an average rating of 7.6 out of 10 from a total of 14 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Attruby side effects |
View all Tafamidis side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Attruby prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Vyndamax, Vyndaqel | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
6 hours |
59 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 23 drugs are known to interact with Attruby:
|
A total of 33 drugs are known to interact with Tafamidis:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
November 22, 2024 |
May 03, 2019 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Tafamidis
Tafamidis (brand name Vyndaqel) is a transthyretin stabilizer that may be given to reduce death or ...
Acoramidis
Acoramidis systemic is used for cardiomyopathy of transthyretin-mediated amyloidosis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.